Related Experiment Videos
Identification of putative nonfunctional steroid receptors in breast and endometrial cancer
D S Colvard1, M L Graham, N J Berg
1Department of Biochemistry, Mayo Graduate School of Medicine, Rochester, MN 55905.
Abstract:
A nuclear binding assay was developed for the purpose of having available a more predictive assay for hormone responsiveness in human cancers. The BNB assay identified specific and saturable steroid nuclear binding in human target tissues and human carcinomas. When the BNB assay was applied to a large set of breast and endometrial carcinomas, we speculate that nonfunctional receptors were detected in 20%-50% of the patients who were receptor-positive by the DCC assay. Lastly, as responsiveness to hormonal therapy in these cancer patients becomes known, the predictive value of the BNB assay can be established.
Insights
A new nuclear binding assay (BNB) offers a more predictive method for assessing hormone responsiveness in human cancers. This assay may identify nonfunctional receptors in a significant portion of patients previously deemed receptor-positive.
Area of Science:
- Oncology
- Endocrinology
- Biochemistry
Background:
- Hormone responsiveness is crucial for predicting treatment outcomes in various human cancers.
- Existing assays for hormone receptors may not always accurately predict therapeutic response.
- There is a need for more predictive assays in cancer diagnostics.
Purpose of the Study:
- To develop a novel nuclear binding assay (BNB) for improved prediction of hormone responsiveness in human cancers.
- To evaluate the specificity and saturability of steroid nuclear binding using the BNB assay.
Main Methods:
- Development of a new nuclear binding assay (BNB).
- Application of the BNB assay to human target tissues and carcinomas.
- Comparison of BNB assay results with the dextran-coated charcoal (DCC) assay in breast and endometrial carcinomas.
Main Results:
- The BNB assay demonstrated specific and saturable steroid nuclear binding in relevant human tissues and cancers.
- A potential discrepancy was observed, with the BNB assay suggesting nonfunctional receptors in 20%-50% of DCC assay-positive patients.
- Further validation is required to correlate BNB assay findings with actual patient response to hormonal therapy.
Conclusions:
- The developed BNB assay shows promise as a more predictive tool for hormone responsiveness in cancer.
- The assay may help identify patients with nonfunctional receptors, potentially refining treatment strategies.
- Establishing the predictive value of the BNB assay requires correlation with clinical outcomes of hormonal therapy.